{"id":71398,"date":"2026-07-30T20:41:49","date_gmt":"2026-07-30T12:41:49","guid":{"rendered":"https:\/\/flcube.com\/?p=71398"},"modified":"2026-07-30T20:41:51","modified_gmt":"2026-07-30T12:41:51","slug":"cspc-pharmaceuticals-nectin-4-targeting-adc-crb-701-receives-fda-approval-for-registrational-trial-in-second-line-oropharyngeal-squamous-cell-carcinoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71398","title":{"rendered":"CSPC Pharmaceutical&#8217;s Nectin-4 Targeting ADC CRB-701 Receives FDA Approval for Registrational Trial in Second-Line Oropharyngeal Squamous Cell Carcinoma"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>CSPC Pharmaceutical Group Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1093:HKG\">HKG: 1093<\/a>) announced that <strong>CRB-701 (SYS 6002)<\/strong>, a next-generation <strong>antibody-drug conjugate (ADC)<\/strong> developed under license from <strong>Corbus Pharmaceuticals<\/strong>, has received <strong>U.S. Food and Drug Administration (FDA) approval to initiate a registrational clinical trial<\/strong> for <strong>second-line (2L) treatment of oropharyngeal squamous cell carcinoma (OPSCC)<\/strong>. The product previously received <strong>Fast Track Designations<\/strong> from the FDA for both <strong>head and neck squamous cell carcinoma (HNSCC)<\/strong> and <strong>cervical cancer<\/strong>, underscoring its potential to address significant unmet needs in multiple oncology indications.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>U.S. FDA<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>IND approval for registrational clinical trial<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>CRB-701 (SYS 6002) \u2013 Nectin-4 targeting ADC<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Second-line (2L) oropharyngeal squamous cell carcinoma (OPSCC)<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Registrational trial (pivotal for potential approval)<\/td><\/tr><tr><td><strong>Licensing Partner<\/strong><\/td><td>Corbus Pharmaceuticals<\/td><\/tr><tr><td><strong>Additional Designations<\/strong><\/td><td>Fast Track for HNSCC and cervical cancer<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-target-validation\" class=\"wp-block-heading\">Drug Profile &amp; Target Validation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target Antigen:<\/strong> <strong>Nectin-4<\/strong>, a clinically validated tumor-associated antigen with established therapeutic relevance<\/li>\n\n\n\n<li><strong>Target Expression Profile:<\/strong><\/li>\n\n\n\n<li><strong>Highly expressed<\/strong> in head and neck squamous cell carcinoma (HNSCC), including OPSCC<\/li>\n\n\n\n<li><strong>Clearly expressed<\/strong> in urothelial carcinoma (validated by enfortumab vedotin approval)<\/li>\n\n\n\n<li><strong>Significant expression<\/strong> in cervical cancer and other solid tumors<\/li>\n\n\n\n<li><strong>Technology Platform:<\/strong> <strong>Next-generation antibody-drug conjugate (ADC)<\/strong> with optimized drug-to-antibody ratio and linker stability<\/li>\n\n\n\n<li><strong>Mechanism of Action:<\/strong> Selective delivery of cytotoxic payload to Nectin-4 expressing tumor cells, minimizing off-target toxicity while maximizing anti-tumor efficacy<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Builds upon clinical validation established by <strong>enfortumab vedotin<\/strong> (Padcev\u00ae) in urothelial carcinoma, but targets different tumor types with high unmet need<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-amp-clinical-need\" class=\"wp-block-heading\">Market Opportunity &amp; Clinical Need<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Oropharyngeal squamous cell carcinoma<\/strong> represents approximately <strong>60-70% of all head and neck cancers<\/strong>, with incidence rates increasing due to <strong>HPV-associated disease<\/strong>. Second-line treatment options remain limited, with <strong>response rates typically below 15%<\/strong> and <strong>median overall survival of 6-9 months<\/strong>. The <strong>global HNSCC market<\/strong> is projected to reach <strong>$3.8 billion by 2028<\/strong>, with significant growth potential for targeted therapies addressing refractory disease.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Key unmet needs addressed by CRB-701:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Limited effective second-line options<\/strong> following platinum-based chemotherapy failure<\/li>\n\n\n\n<li><strong>Poor prognosis<\/strong> in recurrent\/metastatic settings with current standard of care<\/li>\n\n\n\n<li><strong>Need for targeted approaches<\/strong> leveraging validated tumor antigens with favorable safety profiles<\/li>\n\n\n\n<li><strong>Opportunity for biomarker-driven therapy<\/strong> based on Nectin-4 expression levels<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For CSPC Pharmaceutical:<\/strong> Represents significant milestone in <strong>global oncology ambitions<\/strong> and validates international development capabilities beyond traditional Chinese markets<\/li>\n\n\n\n<li><strong>Partnership Value:<\/strong> Demonstrates successful <strong>licensing and development collaboration<\/strong> with U.S.-based Corbus Pharmaceuticals<\/li>\n\n\n\n<li><strong>Regulatory Strategy:<\/strong> <strong>Fast Track Designation<\/strong> provides enhanced FDA interaction and potential for <strong>accelerated approval pathways<\/strong><\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> Success in OPSCC could support <strong>rapid expansion into broader HNSCC and cervical cancer indications<\/strong><\/li>\n\n\n\n<li><strong>Global Positioning:<\/strong> Positions CSPC as competitive player in <strong>next-generation ADC space<\/strong> alongside major pharmaceutical companies<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-next-steps\" class=\"wp-block-heading\">Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Trial Design:<\/strong> Phase II\/III registrational study evaluating <strong>overall response rate (ORR), progression-free survival (PFS), and overall survival (OS)<\/strong> in 2L OPSCC<\/li>\n\n\n\n<li><strong>Patient Selection:<\/strong> Likely to include <strong>Nectin-4 expression as enrichment biomarker<\/strong> based on target validation data<\/li>\n\n\n\n<li><strong>Regulatory Timeline:<\/strong> Target <strong>Biologics License Application (BLA) submission by 2028<\/strong> pending positive trial results<\/li>\n\n\n\n<li><strong>Combination Strategies:<\/strong> Explore potential <strong>combination with immunotherapy agents<\/strong> (PD-1\/PD-L1 inhibitors) for enhanced efficacy<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial opportunities. Actual results may differ due to risks including clinical trial outcomes, regulatory requirements, competitive developments, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072901456_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026072901456_c.\"><\/object><a id=\"wp-block-file--media-433dafa2-9cb3-442d-b279-8378eaf29ed4\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072901456_c.pdf\">2026072901456_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072901456_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-433dafa2-9cb3-442d-b279-8378eaf29ed4\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CSPC Pharmaceutical Group Limited (HKG: 1093) announced that CRB-701 (SYS 6002), a next-generation antibody-drug conjugate&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[35,16,62,171,855],"class_list":["post-71398","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-cancer","tag-clinical-trial-approval-initiation","tag-cspc-pharmaceutical","tag-hkg-1093"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC Pharmaceutical&#039;s Nectin-4 Targeting ADC CRB-701 Receives FDA Approval for Registrational Trial in Second-Line Oropharyngeal Squamous Cell Carcinoma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that CRB-701 (SYS 6002), a next-generation antibody-drug conjugate (ADC) developed under license from Corbus Pharmaceuticals, has received U.S. Food and Drug Administration (FDA) approval to initiate a registrational clinical trial for second-line (2L) treatment of oropharyngeal squamous cell carcinoma (OPSCC). The product previously received Fast Track Designations from the FDA for both head and neck squamous cell carcinoma (HNSCC) and cervical cancer, underscoring its potential to address significant unmet needs in multiple oncology indications.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71398\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC Pharmaceutical&#039;s Nectin-4 Targeting ADC CRB-701 Receives FDA Approval for Registrational Trial in Second-Line Oropharyngeal Squamous Cell Carcinoma\" \/>\n<meta property=\"og:description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that CRB-701 (SYS 6002), a next-generation antibody-drug conjugate (ADC) developed under license from Corbus Pharmaceuticals, has received U.S. Food and Drug Administration (FDA) approval to initiate a registrational clinical trial for second-line (2L) treatment of oropharyngeal squamous cell carcinoma (OPSCC). The product previously received Fast Track Designations from the FDA for both head and neck squamous cell carcinoma (HNSCC) and cervical cancer, underscoring its potential to address significant unmet needs in multiple oncology indications.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71398\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-30T12:41:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-30T12:41:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71398#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71398\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC Pharmaceutical&#8217;s Nectin-4 Targeting ADC CRB-701 Receives FDA Approval for Registrational Trial in Second-Line Oropharyngeal Squamous Cell Carcinoma\",\"datePublished\":\"2026-07-30T12:41:49+00:00\",\"dateModified\":\"2026-07-30T12:41:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71398\"},\"wordCount\":553,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"CSPC Pharmaceutical\",\"HKG: 1093\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71398#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71398\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71398\",\"name\":\"CSPC Pharmaceutical's Nectin-4 Targeting ADC CRB-701 Receives FDA Approval for Registrational Trial in Second-Line Oropharyngeal Squamous Cell Carcinoma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-30T12:41:49+00:00\",\"dateModified\":\"2026-07-30T12:41:51+00:00\",\"description\":\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that CRB-701 (SYS 6002), a next-generation antibody-drug conjugate (ADC) developed under license from Corbus Pharmaceuticals, has received U.S. Food and Drug Administration (FDA) approval to initiate a registrational clinical trial for second-line (2L) treatment of oropharyngeal squamous cell carcinoma (OPSCC). The product previously received Fast Track Designations from the FDA for both head and neck squamous cell carcinoma (HNSCC) and cervical cancer, underscoring its potential to address significant unmet needs in multiple oncology indications.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71398#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71398\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71398#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC Pharmaceutical&#8217;s Nectin-4 Targeting ADC CRB-701 Receives FDA Approval for Registrational Trial in Second-Line Oropharyngeal Squamous Cell Carcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC Pharmaceutical's Nectin-4 Targeting ADC CRB-701 Receives FDA Approval for Registrational Trial in Second-Line Oropharyngeal Squamous Cell Carcinoma - Insight, China&#039;s Pharmaceutical Industry","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that CRB-701 (SYS 6002), a next-generation antibody-drug conjugate (ADC) developed under license from Corbus Pharmaceuticals, has received U.S. Food and Drug Administration (FDA) approval to initiate a registrational clinical trial for second-line (2L) treatment of oropharyngeal squamous cell carcinoma (OPSCC). The product previously received Fast Track Designations from the FDA for both head and neck squamous cell carcinoma (HNSCC) and cervical cancer, underscoring its potential to address significant unmet needs in multiple oncology indications.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71398","og_locale":"en_US","og_type":"article","og_title":"CSPC Pharmaceutical's Nectin-4 Targeting ADC CRB-701 Receives FDA Approval for Registrational Trial in Second-Line Oropharyngeal Squamous Cell Carcinoma","og_description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that CRB-701 (SYS 6002), a next-generation antibody-drug conjugate (ADC) developed under license from Corbus Pharmaceuticals, has received U.S. Food and Drug Administration (FDA) approval to initiate a registrational clinical trial for second-line (2L) treatment of oropharyngeal squamous cell carcinoma (OPSCC). The product previously received Fast Track Designations from the FDA for both head and neck squamous cell carcinoma (HNSCC) and cervical cancer, underscoring its potential to address significant unmet needs in multiple oncology indications.","og_url":"https:\/\/flcube.com\/?p=71398","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-30T12:41:49+00:00","article_modified_time":"2026-07-30T12:41:51+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71398#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71398"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC Pharmaceutical&#8217;s Nectin-4 Targeting ADC CRB-701 Receives FDA Approval for Registrational Trial in Second-Line Oropharyngeal Squamous Cell Carcinoma","datePublished":"2026-07-30T12:41:49+00:00","dateModified":"2026-07-30T12:41:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71398"},"wordCount":553,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Cancer","Clinical trial approval \/ initiation","CSPC Pharmaceutical","HKG: 1093"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71398#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71398","url":"https:\/\/flcube.com\/?p=71398","name":"CSPC Pharmaceutical's Nectin-4 Targeting ADC CRB-701 Receives FDA Approval for Registrational Trial in Second-Line Oropharyngeal Squamous Cell Carcinoma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-30T12:41:49+00:00","dateModified":"2026-07-30T12:41:51+00:00","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that CRB-701 (SYS 6002), a next-generation antibody-drug conjugate (ADC) developed under license from Corbus Pharmaceuticals, has received U.S. Food and Drug Administration (FDA) approval to initiate a registrational clinical trial for second-line (2L) treatment of oropharyngeal squamous cell carcinoma (OPSCC). The product previously received Fast Track Designations from the FDA for both head and neck squamous cell carcinoma (HNSCC) and cervical cancer, underscoring its potential to address significant unmet needs in multiple oncology indications.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71398#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71398"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71398#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC Pharmaceutical&#8217;s Nectin-4 Targeting ADC CRB-701 Receives FDA Approval for Registrational Trial in Second-Line Oropharyngeal Squamous Cell Carcinoma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71398","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71398"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71398\/revisions"}],"predecessor-version":[{"id":71400,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71398\/revisions\/71400"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71398"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71398"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71398"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}